Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2000

View Archived Issues

Connetics achieves significant growth in 1999

Cell Pathways signs commercialization agreement for Aptosyn

Novel compounds to treat thyroid disorders in development at Lotus

Alcon makes milestone payment to Pharmacyclics for Optrin

PEG-rHuMGDF tested as adjunct to chemotherapy in AML

Antisense oligonucleotides targeting TNFR1 expression designed at Isis

Discovery commences pivotal phase III trial of Surfaxin in infants with MAS

Techniclone licenses novel antiangiogenic antibody

Progress during 1999 highlighted by Sepracor

FDA advisory committee recommends approval of Novantrone for MS indication

Trimeris and Roche advance HIV fusion inhibitors in clinical testing

New series from Lilly affecting serotonergic pathways

Subunit-selective GABA-A receptor ligands as safe and effective agents for anxiety

Beta-amyloid peptide inhibitors designed as part of Elan-Lilly collaboration

Roche devotes resources to study of orphan opioid receptor ligands

New radioligands for visualizing DAT in the human brain

Ono discloses N-type calcium channel blockers and their use

New Zeria compounds with alpha1-adrenoceptor-blocking effects

Hydroxamic acid-based MMP inhibitors in the DuPont pipeline

Kosan develops efficient production system for potent anticancer drugs

New patents cover significant improvements to Avigen's AAV vector technology

Cytoclonal reports design and development of new agents for rhinovirus and other viral infections

Merck reports success with early study of HIV-1 integrase inhibitors

EntreMed to commence phase I trial of Angiostatin protein

New oral IBD treatment targets macrophages and microfold cells

Patients prefer Invicorp over Caverject

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...